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Introduction
In contrast to heart failure with a reduced ejection fraction 
(HFrEF), patients with heart failure with a preserved ejection 
fraction (HFpEF) still do not benefit from evidence-based 
treatment options in the absence of a profound knowledge 
about its pathophysiology. Therefore, HFpEF therapy is 
aimed at comorbidities and at reducing signs and symptoms 
of congestion [1]. Indeed, just over a decade ago, knowledge 
about myocardial structure and function in HFpEF was very 
poor [2]. In the following years many studies addressed epi-
demiological, clinical and fundamental aspects in HFpEF. 
This eventually led to a novel paradigm in HFpEF patho-
physiology with a central role for metabolic comorbidities 
on top with downstream effects such as inflammation and 
oxidative stress, eventually interfering with normal myo-
cardial function [3]. Indeed, non-cardiac comorbidities such 
as obesity, arterial hypertension and diabetes mellitus are 
highly prevalent in HFpEF [4]. These comorbidities gen-
erate a chronic, systemic inflammatory state and diverse 
markers of inflammation have been found to be associated 
with the diagnosis and prognosis of HFpEF [5, 6]. Accord-
ing to this HFpEF paradigm, the observed systemic inflam-
mation also leads to myocardial microvascular endothelial 
activation and oxidative stress [3]. At the cardiac level, this 
endothelial inflammation and oxidative stress induce myo-
cardial stiffening.
Although there are many other pathophysiological find-
ings in HFpEF, as recently discussed comprehensively 
elsewhere [7], this review will focus on myocardial abnor-
malities and the interplay between changes in the extracellu-
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Abstract Heart failure with preserved ejection fraction 
(HFpEF) is characterised by a high incidence of metabolic 
comorbidities that share the potential to induce both sys-
temic and coronary microvascular inflammation and oxida-
tive stress. These pathophysiological alterations contribute 
to increased passive stiffness of the myocardium and to 
diastolic dysfunction, both hallmarks of HFpEF. Passive 
myocardial stiffness depends mainly on two components: 
the extracellular matrix (ECM) and the cardiomyocytes. 
Quantitative and qualitative changes in collagen metabo-
lism leading to myocardial fibrosis determine the ECM-
based stiffness of the myocardium. Different noninvasive 
diagnostic tools to assess myocardial fibrosis are being 
developed, some of which have demonstrated to correlate 
with clinical status and prognosis. Cardiomyocytes mainly 
alter the passive stiffness through alterations in the giant 
myofilament titin, which serves as a spring. By modify-
ing its phosphorylation state or by direct oxidative effects, 
titin determines cardiomyocyte-based passive stiffness. 
Probably the relative importance of cardiomyocyte-based 
changes is more important in the beginning of the disease, 
whereas ECM-based changes become more prominent in 
the more advanced stages. The present review focuses on 
these changes in ECM and cardiomyocytes in HFpEF and 
their potential prognostic and therapeutic implications.
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and the cardiomyocytes, in which the giant protein titin 
plays a key regulatory role.
The extracellular matrix in HFpEF
Quantification of collagen content
The first indications about HFpEF pathophysiology were 
based on human myocardial biopsy samples, which showed 
myocardial fibrosis with an increased collagen volume frac-
tion (CVF) in HFpEF patients compared with controls [12]. 
These findings were recently confirmed in patients with an 
ante-mortem diagnosis of HFpEF expressing more myo-
cardial fibrosis on autopsies than in age-matched controls 
[13]. Besides, it was demonstrated that an inflammatory 
trigger, such as is present in HFpEF, can induce the differ-
entiation of myocardial fibroblasts into collagen-producing 
myofibroblasts after stimulation with transforming growth 
factor-β [14].
However, quantification of the total collagen content 
with CVF seems to have less functional implications than 
the relative amount of the stiffer collagen type I over the 
more compliant collagen type III, or the amount of cross-
linked collagen by lysyl oxidase (Fig. 2; [14, 15]). For 
example, human HFpEF myocardial biopsy samples con-
tained increased levels of collagen type I, enhanced colla-
gen cross-linking and lysyl oxidase expression and these 
findings were associated with parameters of diastolic dys-
lar matrix (ECM) and the cardiomyocytes (and specifically 
titin) that cause myocardial stiffening.
Increased myocardial stiffness in HFpEF
The signs and symptoms of HFpEF are based on increased 
myocardial stiffness, leading to diastolic left ventricular 
(LV) dysfunction, which is defined as the inability of the 
heart to fill to an adequate end-diastolic volume at accept-
ably low pressures in the absence of endocardial or pericar-
dial disease [8]. Although practically all patients with heart 
failure, regardless of LV ejection fraction (LVEF), have 
diastolic dysfunction to a greater or lesser degree, HFpEF 
patients have a non-dilated left ventricle with globally pre-
served systolic function (LVEF > 50 %). Diastolic dysfunc-
tion is either diagnosed invasively (by measuring elevated 
pulmonary capillary wedge pressure, LV end-diastolic pres-
sure or prolonged LV isovolumic relaxation) or noninva-
sively with tissue Doppler echocardiography [9, 10].
LV diastole can be subdivided into two components: 
myocardial inactivation and myocardial stiffness. This 
myocardial inactivation is the consequence of dissociating 
contractile myofilaments and calcium reuptake into the sar-
coplasmic reticulum. Myocardial stiffness can be attributed 
to the viscoelastic properties of the myocardium (Fig. 1; 
[11]). The two myocardial compartments that regulate the 
viscoelastic properties and hence myocardial stiffness will 
be discussed next: the ECM, namely the collagen network, 
KEY MESSAGE Diastole consists of an active (myocardial relaxation) and a passive (myocardial stiffness) phase. Myocardial
stiffness is determined by the cardiomyocytes and the extracellular matrix and the relative importance of each varies during the
course of the disease.
Fig. 1 Determinants of diastole. 
LV diastole can be subdivided 
into two components: myocar-
dial inactivation and myocar-
dial stiffness. This myocardial 
inactivation is the consequence of 
dissociating contractile myofila-
ments and calcium reuptake into 
the sarcoplasmic reticulum. Myo-
cardial stiffness can be attributed 
to the viscoelastic properties 
of the myocardium [11]. The 
two myocardial compartments 
that regulate the viscoelastic 
properties and hence myocardial 
stiffness are the ECM and the 
cardiomyocytes, in which the 
giant protein titin plays a key 
regulatory role. (Modified with 
permission from [59])
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ume fraction using MOLLI (Modified Look-Locker inver-
sion recovery) sequences, and equilibrium contrast CMR 
[21]. Indeed, extracellular volume fraction as a marker of 
diffuse myocardial fibrosis correlated with impaired dia-
stolic function in HFpEF [22]. On the other hand, numerous 
biomarkers related to collagen metabolism or its turnover, 
or molecules integrating cardiac stress injury, inflammation 
and fibrosis have been studied. However, blood levels of a 
valid biomarker of myocardial fibrosis should directly cor-
relate with quantitative parameters used to define fibrosis in 
endomyocardial biopsies [23]. Of all possible candidates, 
only PICP (the carboxy-terminal propeptide of procollagen 
type I) and PIIINP (the amino-terminal propeptide of pro-
collagen type III) have been shown to be associated with 
myocardial fibrosis (Fig. 2; [23]). Possibly different bio-
markers of collagen and ECM turnover vary during the tran-
sition from being at risk for HFpEF development to more 
advanced stages of the disease, although further studies are 
needed to validate these biomarkers and their potential role 
in HFpEF diagnosis, treatment and prognosis.
Prognostic relevance of myocardial fibrosis
After fibrosis is detected, its clinical or prognostic conse-
quences need to be established. As mentioned above, extra-
cellular volume fraction can be determined with CMR in 
HFpEF patients as a measure of diffuse myocardial fibro-
sis [22]. Extracellular volume fraction correlated with LV 
end-diastolic and systolic volumes, LV mass, LVEF, peak 
filling rate and peak ejection rate in HFpEF patients [22]. 
A significant association has been reported between CMR 
T1 time (validated in LV endomyocardial biopsies) and 
cardiac outcomes (hospitalisation for heart failure or death 
from cardiovascular causes) in HFpEF patients [24]. How-
ever, further large-scale studies need to establish the prog-
nostic relevance of these findings and their value in clinical 
decision-making.
The number of biomarkers that are currently being stud-
ied or developed reflecting myocardial fibrosis in HFpEF is 
growing exponentially and a detailed discussion of this topic 
is beyond the scope of this review. The most important and 
promising biomarkers were recently discussed elsewhere 
[25]. Especially ST2 and galectin-3 have the potential to 
predict prognosis in HFpEF and, next to this, galectin-3 is 
related to aldosterone signalling and might identify patients 
for treatment with aldosterone antagonists [26]. However, in 
a recent substudy of the RELAX trial, galectin-3 correlated 
with renal dysfunction and, taking this into account, was not 
independently associated with the severity of HFpEF [27]. 
Further research is needed to elucidate the role of biomark-
ers of fibrosis in HFpEF.
function on tissue Doppler echocardiography [16]. Also, it 
was demonstrated that HFpEF patients with diabetes mel-
litus have increased deposition of advanced glycation end-
products in the ECM, which are able to cross-link collagen 
and increase myocardial stiffness (Fig. 2; [17]). Moreover, 
advanced glycation end-products are known to induce myo-
cardial inflammation [18, 19] and oxidative stress [20]. The 
relevance of myocardial inflammation and oxidative stress 
will be discussed in more detail later.
Research has focused on noninvasive techniques to mea-
sure LV myocardial fibrosis to avoid the (low) risk of compli-
cations and sampling error, both inherent to the procurement 
of an endomyocardial biopsy. Cardiac magnetic resonance 
(CMR) imaging, for example, allows for quantification of 
diffuse myocardial fibrosis by measurement of longitudinal 
relaxation time (T1 mapping). Several T1 mapping meth-
ods have been validated with endomyocardial biopsies to 
assess diffuse myocardial fibrosis. These techniques include 
post-contrast T1 mapping, calculation of extracellular vol-
Fig. 2 Schematic representation of the process of collagen fibres for-
mation. (Adapted from [60] with permission). PCP procollagen car-
boxy-terminal propeptide, PNP procollagen amino-terminal propep-
tide, PCPase PCP prcollagen carboxi-pepdtidase, PNP procollagen 
amino-peptidase, AGEs advanced end-glycation products
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operating range of sarcomere length in HFpEF patients is 
unknown. The giant protein titin forms a unique filament 
network in cardiomyocytes, which engages in both mechan-
ical and signalling functions of the heart and will be dis-
cussed in more detail later [31].
Of interest, the functional relevance of myocardial colla-
gen on diastolic dysfunction may depend on the stage of the 
disease as illustrated in a ZSF1 (Zucker diabetic fatty/Spon-
taneously hypertensive heart failure F1 hybrid) rat model in 
which HFpEF is induced by obesity and diabetes mellitus on 
top of arterial hypertension [32]. Twenty-week-old HFpEF 
rats had increased myocardial Fpassive compared with hyper-
tensive controls (without a HFpEF phenotype). However, 
CVF was not increased in these animals compared with the 
control group and the increase in Fpassive was attributed to a 
stiffer cardiomyocyte compartment [32].
Finally, as previously mentioned, not only the quantity of 
collagen but also some qualitative aspects such as the degree 
of collagen cross-linking [33] or the collagen type I: type III 
ratio, with collagen type I being stiffer than collagen type 
III [34], may influence collagen solubility and myocardial 
stiffness. In this regard, in patients with hypertensive heart 
failure, collagen cross-linking but not CVF was associated 
with elevated filling pressures (Fig. 3; [35]). Moreover, an 
increase in insoluble collagen accounts for the increase in 
total collagen and ECM-based Fpassive in HFpEF patients 
[28]. On the other hand, whereas collagen type I expression 
was found to be increased in the myocardium of HFpEF 
patients and associated with the E:E’ ratio, no significant 
changes were found in collagen type III expression [16].
Cardiomyocytes in HFpEF
Next to the observed ECM changes, cardiomyocytes also 
undergo changes in HFpEF. When compared with HFrEF, 
cardiomyocytes in HFpEF patients are larger and stiffer 
with higher Fpassive upon stretch [29]. In cardiomyocytes, the 
Functional relevance of myocardial fibrosis in diastolic 
dysfunction
Associations of myocardial CVF with parameters related to 
diastolic dysfunction such as LV end-diastolic pressure [12] 
or the E:E’ ratio (the ratio of transmitral E velocity to early 
diastolic mitral annular velocity) [16] have been found in 
HFpEF patients (Fig. 3). Moreover, associations between 
collagen-dependent stiffness and pulmonary capillary 
wedge pressure or left atrial diameter have been reported 
[28]. However, it has to be considered that LV end-diastolic 
pressure, LV end-diastolic wall stress and myocardial stiff-
ness modulus, were increased in HFpEF patients versus 
controls, even in those patients with low CVF, suggesting 
that myocardial fibrosis is not the sole contributor to LV dia-
stolic dysfunction [12].
In this regard, in HFpEF patients, passive stiffness 
(Fpassive) of single isolated, membrane-permeabilised car-
diomyocytes was shown to be significantly higher during 
muscle lengthening than in HFrEF, despite increased CVF 
in HFrEF versus HFpEF [29]. Of course these single cardio-
myocyte experiments do not account for ECM-based Fpassive. 
More recently, functional experiments on small myocar-
dial muscle strips allowed the differentiation between car-
diomyocyte- and ECM-based Fpassive. In an HFpEF patient 
population undergoing coronary artery bypass surgery, 
force measurements were performed on epicardial biopsy 
samples obtained during surgery [28]. In these patients, 
ECM-dependent stress was associated with elevated filling 
pressures and left atrial dilatation. At higher muscle and sar-
comere lengths, increases in ECM-based Fpassive account for 
more than two-thirds of total Fpassive in HFpEF [28], which 
suggests that collagen serves as a back-up mechanism to 
prevent supraphysiological stretch [30]. At lower sarco-
mere lengths, the titin-dependent Fpassive was also shown to 
be increased and to correlate with left atrial diameter [28]. 
The relative contributions of titin and collagen to Fpassive are 
therefore dependent on sarcomere length, but the actual 
Fig. 3 Association of (a) col-
lagen volume fraction (CVF) 
and (b) collagen cross-linking 
with left-sided filling pressures 
echocardiographically esti-
mated in heart failure patients 
with preserved ejection fraction 
(HFpEF). (Adapted from [61] 
with permission). E maximum 
early transmitral flow velocity 
in diastole, E’, maximum early 
diastolic velocity of the mitral 
annulus displacement
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leading to increased myocardial Fpassive and cardiomyocyte 
hypertrophy [3]. On top of this pathophysiological cascade 
are metabolic comorbidities such as obesity, diabetes mel-
litus and arterial hypertension that induce a chronic, inflam-
matory state, also affecting the coronary microvascular 
endothelium and leading to oxidative stress [3]. Inflamma-
tion and oxidative stress also reduce nitic oxide (NO) bio-
availability with subsequently less stimulation of soluble 
guanylate cyclase (sGC), which catalyses the conversion of 
guanosine 5’-triphosphate (GTP) to cGMP [49]. Also, direct 
oxidation of sGC leads to a dysfunctional, haeme-free iso-
form which is unresponsive to NO [50]. The finding that 
LV dysfunction and increased myocardial stiffness in dia-
betic mice is attenuated by the inhibition of dipeptidyl pep-
tidase 4 also supports this paradigm, since these effects are 
potentially mediated by the stimulation of the cGMP-PKG 
pathway and the phosphorylation status of titin [51]. This 
cascade is an important potential target for future HFpEF 
therapeutic strategies, which will be discussed in detail in 
another review in this series.
Besides indirect effects via decreased NO-sGC-cGMP-
PKG signalling, oxidative stress can also have direct effects 
on titin-based stiffness (Fig. 4). The N2-Bus, containing 
6 cysteines, has a potential to undergo disulphide bond-
ing under conditions of oxidative stress. Indeed, in atomic 
force experiments it was demonstrated that in the absence 
of reducing agents, up to three titin-stabilising disulphide 
bonds could be formed in N2-Bus, leading to a shorter titin 
length and a secondary increase in Fpassive [52].
Another part of the I-band contains segments that are rich 
in immunoglobulin-like (Ig) domains, which make up the 
majority of elastic titin. Usually parts of these Ig domains 
are folded into crypts and they can become unfolded and 
expose cryptic cysteines to disulphide bonding or S-glutathi-
onylation during stretch [31]. A recent study demonstrated 
that stretching with subsequent S-glutathionylation led to 
persistent unfolded states, which decreases the mechanical 
stability of the parent Ig domain as well as its ability to fold 
and as final result a more extensible state of titin [53]. Espe-
cially when stretched cardiomyocytes were incubated with 
oxidised gluthathione, Fpassive decreased, whereas incubation 
with reduced glutathione increased Fpassive, suggesting that 
also the redox state plays a modifying role in titin-based 
stiffness that needs to be studied in more detail (Fig. 4).
Cardiomyocyte and ECM cross-talk
Cardiomyocytes and myocardial ECM are not two com-
pletely independent compartments and a close interaction 
can be expected. Both have been shown to contribute to 
myocardial stiffness [28] and to be associated with diastolic 
dysfunction [12, 16, 28]. Interestingly the combination of 
giant protein titin operates as a bidirectional spring and gives 
stability to the other myofilaments [36]. Titin determines 
the sarcomeric viscoelasticity, whereas actin and myosin 
mainly contribute to force generation [37]. Titin is able to 
modulate cardiomyocyte-based Fpassive by means of isoform 
switching, phosphorylation and oxidative modifications 
[31]. In the adult human heart, titin exists as two isoforms: a 
longer and more compliant N2BA isoform and a shorter and 
stiffer N2B isoform. The N2BA:N2B ratio changes during 
the course of different heart diseases, but in general the ratio 
increases in eccentric remodelling and decreases in con-
centric remodelling [38]. However, these changes probably 
take place gradually during the course of days to weeks and 
evolve during disease states, whereas phosphorylation and 
oxidative modifications occur much faster [31].
Titin can be divided into certain regions, and espe-
cially the I-band is known to contain two spring elements: 
the N2-B unique sequence (N2-Bus) and a region rich in 
proline, glutamate, valine, and lysine (PEVK) [31]. Many 
serine and threonine residues of titin are already identi-
fied as phosphorylation sites for different protein kinases 
(PK), such as PKA [39], PKC [40], PKG [41], extracel-
lular signal-regulated kinase-2 (ERK2) [42] and Ca2+/
calmodulin-dependent protein kinase-II (CaMKII) [43, 44]. 
Phosphorylation of specific titin sites can alter its disten-
sibility and hence stiffness. For example, in the first stud-
ies in human HFpEF biopsy samples, it was observed that 
in vitro administration of PKA decreased Fpassive in isolated 
cardiomyocytes, suggesting a titin phosphorylation deficit 
in HFpEF [12]. Indeed, relative hypophosphorylation of 
the stiff, N2-B titin-isoform was confirmed in later human 
experiments, which could be corrected upon in vitro admin-
istration of PKA or PKG [45], but also in several small 
(ZSF1-obese rats) and large (old hypertensive dogs) HFpEF 
animal models [32, 46]. On the other hand, phosphoryla-
tion of the PEVK region by PKC increased Fpassive in vitro 
[40], but in the ZSF1-obese rats these specific PEVK sites 
were not hyperphosphorylated compared with controls [32]. 
It was recently suggested that hypophosphorylation of the 
N2-Bus and hyperphosphorylation of the PEVK domain 
can act complementary to elevate passive tension in failing 
human hearts [47]. The clinical relevance of this finding for 
HFpEF needs to be studied in more detail.
For HFpEF, especially the relative hypophosphoryla-
tion of PKG-dependent titin sites, is an interesting finding 
that offers potential therapeutic targets (Fig. 4). Not only 
was titin relatively hypophosphorylated, also PKG activi-
ties were shown to be decreased in human HFpEF myo-
cardium, in combination with decreased cyclic guanosine 
3’,5’-monophosphate (cGMP) concentration, which acti-
vates PKG [48]. In the HFpEF paradigm proposed by Pau-
lus and Tschöpe, decreased cGMP concentration and PKG 
activity are the final steps in a complex pathway, ultimately 
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the cardiomyocytes (e.g. sildenafil), cannot be expected to 
‘cure’ HFpEF. Secondly, changes in cardiomyocyte function 
due to inflammation or oxidative stress may trigger ECM 
changes and, vice versa, ECM changes caused by chemi-
cal or oxidative endothelial-ECM signalling or by mechani-
cal stress can be expected to disturb normal cardiomyocyte 
functioning [55]. Thirdly, the relative importance of the 
ECM and the cardiomyocytes to HFpEF pathophysiology 
is expected to vary during the course of the disease. One 
could hypothesise that in the early phase of the disease, car-
diomyocytes are more determinant of HFpEF pathophysiol-
ogy and that ECM changes are more relevant in later stages. 
Indeed, oxidative stress has many very rapid effects on car-
diomyocyte function due to the nature of reactive oxygen 
species [56]. In contrast, with the transition of fibroblasts 
into myofibroblasts that secrete collagen, the formation of 
more insoluble and stiffer collagen fibres may take longer 
before it has a significant effect. For instance ZSF1-obese 
rats developed an HFpEF phenotype with diastolic dysfunc-
CVF- and cardiomyocyte-dependent stiffness improved the 
association of both individual parameters with diastolic dys-
function [12]. Myocardial cells and the ECM can interact at 
multiple levels. For instance, it has been recently shown that 
necrotic cardiomyocytes release damage associated molecu-
lar patterns (DAMPS) which induce fibroblast activation in 
vitro and myocardial inflammation and fibrosis in vivo [54]. 
Since cardiomyocyte necrosis is more specific to HFrEF 
[3], future studies are needed to address a potential role for 
DAMPS in HFpEF. As hypothesised, the pathophysiology 
of HFpEF starts in the coronary microvasculature, where 
inflammation and oxidative stress trigger a cascade that 
affects both the ECM and cardiomyocytes [3]. The impor-
tance of the endothelium in HFpEF pathophysiology is also 
stressed by the finding of coronary microvasculary rarefac-
tion in HFpEF [13].
This interplay between endothelium, ECM and cardio-
myocytes has several implications. Firstly, therapeutic 
options that target either the ECM (e.g. spironolactone) or 
Fig. 4 The effects of oxidative 
stress on titin and cardiomyocyte-
based stiffness. a Oxidative stress 
induces post-translational modifi-
cations of titin, such as oxida-
tion of cysteines in N2B-unique 
sequence of titin (N2-Bus) caus-
ing disulphide bonding (far left), 
S-glutathionylation of cysteines 
in unfolded Ig domains inhibiting 
domain refolding (left-middle), 
and reduced cGMP-dependent 
protein kinase-G (PKG)–depen-
dent N2-Bus phosphorylation, 
because of oxidation of the 
haeme moiety in soluble guanylyl 
cyclase (sGC) and the ensuing 
blockade of cGMP production 
(right). Graphs in B to D show 
oxidative stress–related effects on 
titin-based passive tension caused 
by S–S bonding within N2-
Bus (b), S-glutathionylation of 
unfolded titin-Ig domains (c), or 
depressed cGMP-PKG pathway 
activation (d). 5′GMP guanosine-
5′-monophosphate, cGMP cyclic 
guanosine monophosphate, G 
glutathione, GSSG, glutathione-
disulphide, NO, nitric oxide, P, 
titin phosphorylation, PDE5, 
phosphodiesterase-5, pGC, par-
ticulate guanylyl cyclase, PKG, 
cGMP-dependent protein kinase-
G, and sGC, soluble guanylyl 
cyclase. (Used with permission 
from [62])
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tion and elevated filling pressures and an increased myocar-
dial Fpassive without any change in ECM turnover at 20 weeks 
of age [32]. On the other hand, in more advanced stages of 
HFpEF, the ECM seems to be more prominent and capillary 
rarefaction can be observed [13, 28].
This hypothesis has important therapeutic implications. 
If cardiomyoctes predominate the initial phases of HFpEF, 
it is probably useful to improve cGMP-PKG signalling 
to reduce cardiomyocyte Fpassive [57]. However, at more 
advanced stages of HFpEF, correcting cGMP-PKG signal-
ling might have less effects and drugs targeting myocar-
dial fibrosis (e.g. mineralocorticoid receptor antagonists) 
or more specific processes such as collagen cross-linking 
(e.g. anti-lysyl oxidase) could prove more effective. This 
is illustrated by the results from the RELAX trial [58]. In 
the RELAX trial, chronic treatment with sildenafil was used 
with the rationale that this would inhibit cGMP breakdown 
and increase its concentrations, leading to higher levels 
of PKG. However, sildenafil appeared to have no benefi-
cial effects in this advanced HFpEF population. Therefore, 
future trials should test different therapeutic strategies based 
on different phases of HFpEF. Possibly, circulating ECM 
biomarkers and/or imaging techniques such as T1 mapping 
with CMR will help in identifying which patients might 
benefit most from each therapy.
Conclusions
HFpEF is a complex disease of which the pathophysiology 
is gradually becoming unravelled. Both structural and func-
tional alterations in cardiomyocytes and the ECM have been 
reported, leading to increased myocardial Fpassive. However, 
further mechanistic studies are necessary to elucidate the 
relative contribution and interplay between the two mecha-
nisms, which may depend on the aetiology and comorbidi-
ties as well as on the stage of the disease.
On the other hand, it is essential to develop noninvasive 
biomarkers for the early identification of the alterations in 
these two components. For instance, noninvasive techniques 
such as CMR with T1 mapping and circulating ECM bio-
markers are promising, although future studies are needed 
to assess their potential to truly diagnose, stage or predict 
outcome and response to therapeutic strategies in HFpEF.
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